	US 12,275,799 B2
	Binding agents targeting TROP2-expressing tumor cells
Wenyang Hou, Montréal (CA); Shugang Yao, Montréal (CA); Luis Da Cruz, Montréal (CA); and David S. Young, Montréal (CA)
Assigned to KisoJi Biotechnology Inc., Montreal (CA)
Filed by KisoJi Biotechnology Inc., Montréal (CA)
Filed on May 14, 2024, as Appl. No. 18/664,091.
Application 18/664,091 is a continuation of application No. 18/620,397, filed on Mar. 28, 2024.
Application 18/620,397 is a continuation of application No. PCT/CA2022/051437, filed on Sep. 28, 2022.
Claims priority of provisional application 63/326,572, filed on Apr. 1, 2022.
Claims priority of provisional application 63/249,728, filed on Sep. 29, 2021.
Prior Publication US 2024/0317887 A1, Sep. 26, 2024
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/30 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/732 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)]

23 Claims

1. A single domain antibody (sdAb) that binds to TROP2 comprising a VHH, wherein the VHH comprises:

a CDRH1 having the amino acid sequence set forth in SEQ ID NO:63,

a CDRH2 having the amino acid sequence set forth in SEQ ID NO:64, and

a CDRH3 having the amino acid sequence set forth in SEQ ID NO:65.